


PRODUCT INFORMATION



Griseofulvin

Item No. 19461

CAS Registry No.: 126-07-8
Formal Name: 7-chloro-2',4,6-trimethoxy-6'R-methyl-spiro[benzofuran-2(3H)-1'S-[2]cyclohexene]-3,4'-dione
MF: C₁₇H₁₇ClO₆
FW: 352.8
Purity: ≥98%
UV/Vis.: λ_{max}: 210, 291 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years
Item Origin: Synthetic



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Griseofulvin is supplied as a crystalline solid. A stock solution may be made by dissolving the griseofulvin in the solvent of choice, which should be purged with an inert gas. Griseofulvin is slightly soluble in chloroform and ethyl acetate.

Description

Griseofulvin is a polyketide synthase-derived fungal metabolite originally isolated from *P. griseofulvum* with antifungal and anticancer activities.^{1,2} It inhibits microtubule assembly when used at concentrations ranging from 20 to 200 μM.³ Griseofulvin is active against a variety of dermatophytes (MICs = 0.14-0.42 μg/ml) and reduces the number of infected hair follicles in a guinea pig model of *M. canis* infection when administered at a dose of 60 mg/kg.^{4,5} It also reduces viability of a variety of human colorectal cancer cells *in vitro* and induces abnormal mitotic spindle formation and cell cycle arrest at the G₂/M phase in HT-29 cells when used at a concentration of 20 μM.⁶ Griseofulvin (50 mg/kg) reduces tumor growth in a COLO 205 mouse xenograft model. Formulations containing griseofulvin have been used in the treatment of dermatophyte infections of the skin and nails.

References

1. Cacho, R.A., Chooi, Y.-H., Zhou, H., *et al.* Complexity generation in fungal polyketide biosynthesis: A spirocycle-forming P450 in the concise pathway to the antifungal drug griseofulvin. *ACS Chem. Biol.* **8**(10), 2322-2330 (2013).
2. Flint, A., Forsey, R.R., and Usher, B. Griseofulvin, a new oral antibiotic for the treatment of fungous infections of the skin. *Can. Med. Assoc. J.* **81**(3), 173-175 (1959).
3. Roobol, A., Gull, K., and Pogson, C.I. Inhibition by griseofulvin of microtubule assembly *in vitro*. *FEBS Lett.* **67**(3), 248-251 (1976).
4. Roth, F.J., Jr., Sallman, B., and Blank, H. *In vitro* studies of the antifungal antibiotic griseofulvin. *J. Invest. Dermatol.* **33**, 403-418 (1959).
5. Gentles, J.C. Experimental ringworm in guinea pigs: Oral treatment with griseofulvin. *Nature* **182**(4633), 476-477 (1958).
6. Ho, Y.-S., Duh, J.-S., Jeng, J.-H., *et al.* Griseofulvin potentiates antitumorigenesis effects of nocodazole through induction of apoptosis and G₂/M cell cycle arrest in human colorectal cancer cells. *Int. J. Cancer* **91**(3), 393-401 (2001).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/05/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM